BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
0.7202
+0.0110 (1.55%)
At close: Aug 25, 2026, 4:00 PM EDT
0.7273
+0.0071 (0.99%)
After-hours: Aug 25, 2026, 7:30 PM EDT
BeyondSpring Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
44
Market Cap
29.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.35M | - | - |
| Dec 31, 2021 | 1.35M | 1.17M | 650.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
BYSI News
- 11 days ago - BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 11 days ago - BeyondSpring Quarterly report: Q2 2026 - Filings
- 11 days ago - BeyondSpring Earnings release: Q2 2026 - Filings
- 6 weeks ago - BeyondSpring Slides: Corporate presentation - Filings
- 2 months ago - BeyondSpring appoints Min Qiu as CEO, Na Li as CFO - TheFly
- 2 months ago - BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value - GlobeNewsWire
- 3 months ago - BeyondSpring announces updated data from 303 Study - TheFly
- 3 months ago - BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026 - GlobeNewsWire